Immunome (IMNM)
Market Price (11/20/2026): $16.62 | Market Cap: $2.0 BilSector: Health Care | Industry: Biotechnology
Immunome (IMNM)
Market Price (11/20/2026): $16.62Market Cap: $2.0 BilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -24% Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Biopharmaceutical R&D, Show more. | Meaningful short interestShort Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 12.77, Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 14% | Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -301 Mil Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is null, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -35% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -20% Key risksIMNM key risks include [1] a critical need for additional funding due to a history of significant operating losses, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -24% |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Biopharmaceutical R&D, Show more. |
| Meaningful short interestShort Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 12.77, Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 14% |
| Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -301 Mil |
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is null, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -35% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -20% |
| Key risksIMNM key risks include [1] a critical need for additional funding due to a history of significant operating losses, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Nov 16: down 6.2% in one day (S&P 500 down 1.9%)
The stock declined without company-specific news, as the broader market also fell. The S&P 500 was pulled lower, with headlines noting Nvidia tugged the market lower and chip stocks were a drag.
Down 44.8% from its Aug 19 high to Oct 16 (S&P 500 down 0.5%)
The stock saw a substantial decline over the period, with the biggest single-day drop following the report of inducement grants on October 6. Other significant drops during the run occurred without company-specific news.
Nov 10: down 3.7% the day after its Nov 9 earnings report (S&P 500 down 0.4%)
The stock fell after reporting Q3 results, which included a wider-than-expected loss and analysts cutting forecasts. The company reported $0M revenue and a net loss of $-86M.
Nov 16: down 6.2% in one day (S&P 500 down 1.9%)
The stock declined without company-specific news, as the broader market also fell. The S&P 500 was pulled lower, with headlines noting Nvidia tugged the market lower and chip stocks were a drag.
Down 44.8% from its Aug 19 high to Oct 16 (S&P 500 down 0.5%)
The stock saw a substantial decline over the period, with the biggest single-day drop following the report of inducement grants on October 6. Other significant drops during the run occurred without company-specific news.
Nov 10: down 3.7% the day after its Nov 9 earnings report (S&P 500 down 0.4%)
The stock fell after reporting Q3 results, which included a wider-than-expected loss and analysts cutting forecasts. The company reported $0M revenue and a net loss of $-86M.
Show less
Stock Movement Drivers
Fundamental Drivers
The -27.0% change in IMNM stock from 7/31/2026 to 11/19/2026 was primarily driven by a null change in the company's Total Revenues ($ Mil).| (LTM values as of) | 7312026 | 11192026 | Change |
|---|---|---|---|
| Stock Price ($) | 22.76 | 16.61 | -27.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 4 | 0 | |
| P/S Multiple | 641.3 | ∞ | 9.2233720368547763E17% |
| Shares Outstanding (Mil) | 113 | 114 | -0.4% |
| Cumulative Contribution | 0.0% |
Market Drivers
7/31/2026 to 11/19/2026| Return | Correlation | |
|---|---|---|
| IMNM | -27.0% | |
| Market (SPY) | -3.9% | 40.1% |
| Sector (XLV) | 9.6% | 34.1% |
Fundamental Drivers
The -27.6% change in IMNM stock from 4/30/2026 to 11/19/2026 was primarily driven by a null change in the company's Total Revenues ($ Mil).| (LTM values as of) | 4302026 | 11192026 | Change |
|---|---|---|---|
| Stock Price ($) | 22.94 | 16.61 | -27.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 7 | 0 | |
| P/S Multiple | 313.7 | ∞ | 9.2233720368547763E17% |
| Shares Outstanding (Mil) | 95 | 114 | -16.4% |
| Cumulative Contribution | 0.0% |
Market Drivers
4/30/2026 to 11/19/2026| Return | Correlation | |
|---|---|---|
| IMNM | -27.6% | |
| Market (SPY) | 0.1% | 33.9% |
| Sector (XLV) | 22.6% | 29.0% |
Fundamental Drivers
The 3.4% change in IMNM stock from 10/31/2025 to 11/19/2026 was primarily driven by a 9.2233720368547763E17% change in the company's P/S Multiple.| (LTM values as of) | 10312025 | 11192026 | Change |
|---|---|---|---|
| Stock Price ($) | 16.07 | 16.61 | 3.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 13 | 0 | |
| P/S Multiple | 111.1 | ∞ | 9.2233720368547763E17% |
| Shares Outstanding (Mil) | 87 | 114 | -23.4% |
| Cumulative Contribution | 0.0% |
Market Drivers
10/31/2025 to 11/19/2026| Return | Correlation | |
|---|---|---|
| IMNM | 3.4% | |
| Market (SPY) | 6.1% | 36.2% |
| Sector (XLV) | 25.1% | 28.8% |
Fundamental Drivers
The 88.7% change in IMNM stock from 10/31/2023 to 11/19/2026 was primarily driven by a 9.2233720368547763E17% change in the company's P/S Multiple.| (LTM values as of) | 10312023 | 11192026 | Change |
|---|---|---|---|
| Stock Price ($) | 8.80 | 16.61 | 88.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 7 | 0 | |
| P/S Multiple | 16.2 | ∞ | 9.2233720368547763E17% |
| Shares Outstanding (Mil) | 12 | 114 | -89.3% |
| Cumulative Contribution | 0.0% |
Market Drivers
10/31/2023 to 11/19/2026| Return | Correlation | |
|---|---|---|
| IMNM | 88.7% | |
| Market (SPY) | 77.5% | 33.7% |
| Sector (XLV) | 49.8% | 30.2% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| IMNM Return | 34% | -83% | 384% | -1% | 102% | -23% | 72% |
| Peers Return | 5% | -26% | -1% | -40% | 53% | -3% | -31% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 8% | 97% |
Monthly Win Rates [3] | |||||||
| IMNM Win Rate | 25% | 25% | 58% | 50% | 67% | 45% | |
| Peers Win Rate | 42% | 45% | 48% | 43% | 50% | 49% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 36% | |
Max Drawdowns [4] | |||||||
| IMNM Max Drawdown | -71% | -84% | -33% | -66% | -53% | -45% | |
| Peers Max Drawdown | -45% | -60% | -50% | -63% | -54% | -53% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: CLDX, CTMX, MGNX, STRO, AMGN.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 11/19/2026 (YTD)
How Low Can It Go
| Event | IMNM | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -43.8% | -18.8% |
| % Gain to Breakeven | 78.1% | 23.1% |
| Time to Breakeven | 100 days | 79 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -12.4% | -9.5% |
| % Gain to Breakeven | 14.1% | 10.5% |
| Time to Breakeven | 2 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -22.0% | -6.7% |
| % Gain to Breakeven | 28.2% | 7.1% |
| Time to Breakeven | 4 days | 31 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -84.0% | -24.5% |
| % Gain to Breakeven | 524.6% | 32.4% |
| Time to Breakeven | 614 days | 427 days |
In The Past
Immunome's stock fell -43.8% during the 2025 US Tariff Shock. Such a loss loss requires a 78.1% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | IMNM | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -43.8% | -18.8% |
| % Gain to Breakeven | 78.1% | 23.1% |
| Time to Breakeven | 100 days | 79 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -22.0% | -6.7% |
| % Gain to Breakeven | 28.2% | 7.1% |
| Time to Breakeven | 4 days | 31 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -84.0% | -24.5% |
| % Gain to Breakeven | 524.6% | 32.4% |
| Time to Breakeven | 614 days | 427 days |
In The Past
Immunome's stock fell -43.8% during the 2025 US Tariff Shock. Such a loss loss requires a 78.1% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Immunome (IMNM)
Immunome, Inc. (IMNM) is a biopharmaceutical company focused on the discovery and development of antibody therapeutics for critical medical needs. The company operates at the forefront of biological medicine, aiming to create innovative treatments for both oncology (cancer) and infectious diseases. Immunome's core business revolves around leveraging the power of antibodies to target disease-causing mechanisms and enhance the body's natural defenses.
The company's pipeline features two key programs. In oncology, its lead candidate is IMM-ONC-01, an antibody therapeutic specifically designed to target IL-38. IL-38 is identified as a tumor-derived immune checkpoint, meaning it's utilized by cancer cells to evade detection and destruction by the immune system. By neutralizing IL-38, IMM-ONC-01 seeks to restore or boost the immune response against tumors. For infectious diseases, Immunome is developing IMM-BCP-01, an antibody cocktail product candidate intended for the treatment of SARS-CoV-2 infections and the resulting COVID-19 disease.
Immunome's main products are these advanced antibody therapeutics, and its primary market consists of patients afflicted with serious conditions such as cancer and specific infectious diseases, initially focusing on SARS-CoV-2/COVID-19. The company aims to address significant unmet medical needs globally, with its therapies ultimately being prescribed by healthcare professionals and integrated into existing healthcare systems to improve patient outcomes.
AI Analysis | Feedback
Here are 1-3 brief analogies to describe Immunome (IMNM):
- Regeneron for early-stage antibody drugs in cancer and COVID-19.
- A nascent Genentech, but focused on antibody therapies for oncology and viral infections.
AI Analysis | Feedback
- IMM-ONC-01: An oncology antibody therapeutic program targeting IL-38 to promote immune system evasion.
- IMM-BCP-01: An antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19.
AI Analysis | Feedback
Immunome, Inc. (symbol: IMNM) is a biopharmaceutical company primarily focused on the discovery and development of antibody therapeutics for oncology and infectious disease. Based on the provided background information, the company is engaged in advancing its lead oncology program (IMM-ONC-01) and an antibody cocktail product candidate for infectious disease (IMM-BCP-01).
As a company primarily involved in the research and development phase with pipeline "product candidates," Immunome does not currently have major direct customers in the traditional sense of selling commercialized products to individuals or other companies.
Typically, a biopharmaceutical company at this stage aims to develop its drug candidates through clinical trials. If successful, these candidates may eventually be:
- Licensed to larger pharmaceutical companies for further development, manufacturing, and commercialization. In this scenario, the licensing partners would be considered their "customers" in a business-to-business relationship.
- Commercialized directly by Immunome, which would involve selling to healthcare providers (e.g., hospitals, clinics, pharmacies) or government health organizations.
However, based solely on the description of Immunome's current activities as "discovering and developing" "product candidates," there are no identifiable major customers for commercial products at this time.
AI Analysis | Feedback
AI Analysis | Feedback
Clay Siegall, Ph.D. President & Chief Executive Officer
Dr. Siegall was appointed President & Chief Executive Officer of Immunome in October 2023. He previously served as CEO of Morphimmune, a privately held biotechnology company that successfully merged with Immunome under his leadership. Dr. Siegall is also a co-founder and former CEO of Seagen, Inc., which was acquired by Pfizer for $43 billion. He has over 25 years of experience in the biopharmaceutical industry.
Max Rosett Chief Financial Officer
Mr. Rosett joined Immunome in October 2023, following the company's merger with Morphimmune, where he previously served as Acting Chief Operating Officer. Before Morphimmune, he was a Principal at Research Bridge Partners, a life science investment firm. Mr. Rosett also worked as a software engineer at Google and began his career at the Boston Consulting Group, advising clients in the pharmaceutical industry.
Jack Higgins, Ph.D. Chief Scientific Officer
Dr. Higgins is the Chief Scientific Officer at Immunome.
Kinney Horn Chief Business Officer
Mr. Horn serves as the Chief Business Officer, bringing over two decades of experience in life science finance and business development to Immunome.
Bob Lechleider, M.D. Chief Medical Officer
Dr. Lechleider holds the position of Chief Medical Officer at Immunome.
AI Analysis | Feedback
Immunome, Inc. (IMNM) faces several key risks inherent to its operations as a biopharmaceutical company focused on discovering and developing antibody therapeutics. These risks are primarily centered around the challenging and costly nature of drug development, market competition, and financial sustainability.
- Clinical Trial and Regulatory Approval Risk: As a biopharmaceutical company, Immunome's success is heavily dependent on the successful outcome of its clinical trials and the ability to secure regulatory approvals for its product candidates. The drug development process is lengthy, expensive, and uncertain, with a high rate of failure at various stages. Even with positive Phase 3 results for a lead candidate like varegacestat, there is no guarantee of New Drug Application (NDA) submission leading to regulatory approval or successful commercialization.
- Product Pipeline Concentration and Commercialization Challenges: Immunome's future revenue and profitability are largely tied to the success of a limited number of product candidates. While the company has demonstrated progress with its varegacestat program and has other candidates like IM-1021 in earlier phases and planned IND submissions, the commercial success of these assets is not assured. The market for desmoid tumors, for which varegacestat is being developed, is small, and the company faces intense competition from existing treatments and other companies with greater financial resources and established market presence in both oncology and infectious disease fields.
- Financial Sustainability and Need for Additional Funding: Immunome is a development-stage company with minimal current revenue and a history of significant operating losses. Advancing product candidates through clinical development to potential commercialization requires substantial capital. Although the company recently conducted a public offering to extend its cash runway, there remains a risk of needing to raise additional capital in the future, which could lead to further shareholder dilution or impact the company's ability to fund its research and development activities.
AI Analysis | Feedback
The rapidly evolving landscape of COVID-19 treatment and prevention, including the emergence of highly effective oral antivirals, widespread vaccination, and the continuous evolution of SARS-CoV-2 variants, poses a significant threat to the market viability and relevance of Immunome's antibody cocktail product candidate, IMM-BCP-01, for SARS-CoV-2 infections and COVID-19.
AI Analysis | Feedback
Immunome (NASDAQ: IMNM) focuses on developing antibody therapeutics for oncology and infectious diseases.
IMM-ONC-01 (Oncology)
Immunome's lead oncology program, IMM-ONC-01, targets IL-38, a tumor-derived immune checkpoint. While a specific addressable market size for IL-38 inhibitors is not readily available, IMM-ONC-01 falls under the broader categories of Immuno-Oncology (IO) and Immune Checkpoint Inhibitors.
- The global immuno-oncology (IO) market was estimated at approximately USD 43.73 billion in 2023 and is projected to reach around USD 284.29 billion by 2033. Another estimate places the global immuno-oncology (IO) market size at USD 54.35 billion in 2025, projected to hit approximately USD 435.70 billion by 2035.
- The global immune checkpoint inhibitors market was valued at an estimated USD 48.42 billion in 2023 and is projected to reach USD 154.25 billion by 2030. This market was valued at USD 66.2 billion in 2025 and is expected to grow to USD 303.9 billion in 2035.
- North America has consistently dominated these markets, holding the largest share in 2023, 2024, and 2025.
IMM-BCP-01 (SARS-CoV-2/COVID-19)
IMM-BCP-01 was an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. However, the development of IMM-BCP-01 has been discontinued.
AI Analysis | Feedback
Immunome (IMNM) is poised for potential future revenue growth over the next 2-3 years, driven primarily by the advancement and potential commercialization of its oncology pipeline. The company's focus is on developing first-in-class and best-in-class targeted cancer therapies.
- Regulatory Approval and Commercialization of Varegacestat (formerly AL102) for Desmoid Tumors: Immunome's lead program, varegacestat, a once-daily oral gamma secretase inhibitor, achieved positive topline results from the pivotal Phase 3 RINGSIDE trial in December 2025. This trial demonstrated an 84% reduction in the risk of disease progression or death and a 56% objective response rate in patients with desmoid tumors. An New Drug Application (NDA) submission for varegacestat is planned for the second quarter of 2026. Successful regulatory approval and subsequent commercial launch would be a significant new revenue stream, with estimated conservative peak global sales potentially reaching $280 million.
- Advancement and Potential Commercialization of IM-1021 (ROR1 ADC): Immunome is progressing IM-1021, a ROR1-targeted Antibody-Drug Conjugate (ADC), through its Phase 1 clinical trial for solid tumors and B-cell lymphomas. The company received IND clearance for IM-1021 in the fourth quarter of 2024, and initial data from the ongoing Phase 1 study is anticipated in 2026. IM-1021 incorporates Immunome's proprietary TOP1 inhibitor, HC74, designed to overcome common ADC resistance mechanisms. Positive clinical outcomes and progression to later-stage development or potential partnerships could drive future revenue.
- Progression of IM-3050 (FAP-targeted Radiotherapy) into Clinical Development: IM-3050, a Fibroblast Activating Protein (FAP)-targeted lutetium-177 radioligand therapy, received IND clearance in April 2025, with the initiation of a Phase 1 clinical trial expected in early 2026 or the second half of 2025. Successful advancement of this novel therapeutic modality could create future revenue opportunities through development milestones, licensing agreements, or eventual commercialization.
- Expansion and Advancement of the Broader Antibody-Drug Conjugate (ADC) Pipeline: Beyond IM-1021, Immunome is actively building a robust pipeline of early-stage ADCs targeting various solid tumors. The company has three preclinical solid-tumor ADCs (IM-1617, IM-1340, IM-1335) with IND-enabling work underway and anticipated IND submissions in 2026. The strategic focus on developing differentiated ADCs with novel targets presents multiple opportunities for future collaboration revenue, milestone payments, and potential product sales as these programs advance.
AI Analysis | Feedback
Share Issuance
- A new shelf registration for up to approximately $156 million in common stock was reported on March 11, 2026.
- An underwritten public offering in December 2025 raised $460.5 million in gross proceeds, extending the projected cash runway into 2028.
- In January 2025, Immunome announced plans for an underwritten public offering to issue and sell $125.0 million of shares of its common stock.
Inbound Investments
- In October 2023, Immunome completed a merger with Morphimmune, which included a $125 million private placement investment from leading institutional investors such as Enavate Sciences, EcoR1 Capital, Redmile Group, Janus Henderson Investors, Avidity Partners, and Woodline Partners LP.
- Redmile Group increased its position in Immunome during the fourth quarter of 2025 by 695,000 shares, an estimated $12.20 million trade, bringing their stake to 9.05% of their 13F assets under management as of December 31, 2025.
Outbound Investments
- In January 2024, Immunome licensed ZPC-21 (now IM-1021), a ROR1 antibody-drug conjugate, and ADC platform technology from Zentalis Pharmaceuticals, with an upfront payment of $35 million in cash and Immunome stock, and potential milestones of up to $275 million plus royalties.
- On March 26, 2024, Immunome completed the acquisition of varegacestat (formerly AL102) and AL101 from Ayala Pharmaceuticals for an upfront payment of $20 million in cash and $30 million in Immunome common stock, along with an additional $37.5 million in milestones.
- On December 26, 2023, Immunome announced the acquisition of antibody-related assets and materials from Atreca for an upfront payment of $5.5 million, with potential for an additional $7 million in clinical development milestones.
Capital Expenditures
- Research and development expenses for the year ended December 31, 2025, were $177.3 million.
- In-process research and development expenses for the year ended December 31, 2025, were $10.0 million, specifically tied to a development milestone for the Phase 3 RINGSIDE trial of varegacestat.
- Funds from recent offerings are intended to support the potential commercial launch of varegacestat and the further development of their pipeline, with the company expecting its current cash to fund operations into 2028.
Peer Outperformance in Biotechnology
| Industry | Names | 1Y med | 3Y med | 5Y med | Top 3 by 5Y |
|---|---|---|---|---|---|
| Health Care Distributors | 5 | 20.1% | 78.5% | 200.4% | CAH 522% · MCK 393% · COR 200% |
| Health Care Services | 20 | 29.8% | 19.4% | 13.7% | RDNT 146% · HIMS 119% · DGX 92% |
| Managed Health Care | 8 | 54.9% | -10.9% | -9.1% | OSCR 154% · HQY 59% · ELV 1% |
| Health Care Facilities | 26 | 14.5% | 11.8% | -10.2% | THC 240% · NHC 208% · EHC 184% |
| Health Care Equipment | 50 | -1.7% | 2.7% | -17.2% | GKOS 395% · UFPT 330% · TMDX 313% |
| Health Care Supplies | 11 | 22.8% | -2.2% | -40.4% | LNTH 256% · HAE 114% · MMSI 22% |
| Pharmaceuticals | 60 | -15.9% | -1.5% | -42.0% | LQDA 1229% · KNSA 667% · XERS 632% |
| Life Sciences Tools & Services | 110 | -21.8% | -26.1% | -74.7% | AXGN 477% · NTRA 181% · MEDP 179% |
| Biotechnology ← | 370 | -35.1% | -42.2% | -84.4% | ELVN 1306% · TRVI 1194% · DNTH 1168% |
| Health Care Technology | 23 | -20.5% | -61.1% | -88.1% | VEEV -14% · DOCS -52% |
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Immunome Earnings Notes | 12/16/2025 | |
| Can Immunome Stock Hold Up When Markets Turn? | 10/17/2025 | |
| Immunome Stock Jumps 7.5% In A Day, Why You Shouldn Not Be Buying The Stock | 08/09/2025 | |
| Immunome (IMNM) Operating Cash Flow Comparison | 08/08/2025 | |
| Immunome (IMNM) Net Income Comparison | 08/08/2025 | |
| Immunome (IMNM) EBITDA Comparison | 08/08/2025 | |
| Immunome (IMNM) Debt Comparison | 08/08/2025 | |
| Immunome (IMNM) Revenue Comparison | 08/08/2025 | |
| Immunome (IMNM) Tax Expense Comparison | 08/08/2025 | |
| Immunome (IMNM) Operating Income Comparison | 08/08/2025 | |
| ARTICLES | ||
| Small Cap Stocks Trading At 52-Week High | 12/17/2025 | |
| IMNM Stock Up 36% after 6-Day Win Streak | 07/24/2025 | |
| IMNM Stock Up 32% after 5-Day Win Streak | 07/23/2025 |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 12.67 |
| Mkt Cap | 1.2 |
| Rev LTM | 30 |
| Op Inc LTM | -105 |
| FCF LTM | -90 |
| FCF 3Y Avg | -122 |
| CFO LTM | -90 |
| CFO 3Y Avg | -120 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | -72.5% |
| Rev Chg 3Y Avg | 0.1% |
| Rev Chg Q | -35.5% |
| QoQ Delta Rev Chg LTM | -1.3% |
| Op Inc Chg LTM | -6.3% |
| Op Inc Chg 3Y Avg | -12.8% |
| Op Mgn LTM | -254.7% |
| Op Mgn 3Y Avg | -154.9% |
| QoQ Delta Op Mgn LTM | -23.7% |
| CFO/Rev LTM | -287.0% |
| CFO/Rev 3Y Avg | -163.8% |
| FCF/Rev LTM | -287.7% |
| FCF/Rev 3Y Avg | -164.4% |
FDA Approved Drugs Data
Expand for More| Post-Approval Fwd Returns | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| FDA App # | Brand Name | Generic Name | Dosage Form | FDA Approval | 3M Rtn | 6M Rtn | 1Y Rtn | 2Y Rtn | Total Rtn |
| BLA761115 | TRODELVY | sacituzumab govitecan-hziy | injectable | 4222020 | |||||
| Post-Approval Fwd Returns | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| FDA App # | Brand Name | Generic Name | Dosage Form | FDA Approval | 3M Rtn | 6M Rtn | 1Y Rtn | 2Y Rtn | Total Rtn |
| BLA761115 | TRODELVY | sacituzumab govitecan-hziy | injectable | 4222020 | |||||
Segment Financials
Revenue by Segment| $ Mil | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Development of targeted oncology therapies | 7 | 9 | 14 | 0 |
| Total | 7 | 9 | 14 | 0 |
| $ Mil | 2025 | 2024 | 2023 |
|---|---|---|---|
| Development of targeted oncology therapies | -224 | -306 | -110 |
| Total | -224 | -306 | -110 |
| $ Mil | 2025 | 2024 | 2023 |
|---|---|---|---|
| Development of targeted oncology therapies | -212 | -293 | -107 |
| Total | -212 | -293 | -107 |
| $ Mil | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Development of targeted oncology therapies | 149 | 24 | 58 | 45 | 5 |
| Total | 149 | 24 | 58 | 45 | 5 |
Price Behavior
| Market Price | $16.61 | |
| Market Cap ($ Bil) | 1.9 | |
| First Trading Date | 10/02/2020 | |
| Distance from 52W High | -44.3% | |
| 50 Days | 200 Days | |
| DMA Price | $19.92 | $22.03 |
| DMA Trend | down | down |
| Distance from DMA | -16.6% | -24.6% |
| 3M | 1YR | |
| Volatility | 55.2% | 60.6% |
| Downside Capture | 314.39 | 190.56 |
| Upside Capture | 114.23 | 164.56 |
| Correlation (S&P 500) | 40.9% | 35.5% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.99 | 1.36 | 1.75 | 1.23 | 1.63 | 1.59 |
| Up Beta | -1.22 | 1.87 | 1.65 | 1.58 | 2.18 | 1.33 |
| Down Beta | -1.67 | -0.70 | 0.64 | 1.09 | 1.10 | 1.44 |
| Up Capture | 79% | 51% | 150% | 79% | 212% | 859% |
| Bmk +ve Days | 12 | 18 | 28 | 62 | 130 | 427 |
| Stock +ve Days | 10 | 18 | 32 | 65 | 128 | 371 |
| Down Capture | 291% | 309% | 248% | 143% | 136% | 112% |
| Bmk -ve Days | 10 | 25 | 36 | 64 | 121 | 325 |
| Stock -ve Days | 12 | 25 | 32 | 61 | 122 | 372 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with IMNM | |
|---|---|---|---|---|
| IMNM | -7.0% | 60.6% | 0.11 | - |
| Sector ETF (XLV) | 18.3% | 17.1% | 0.80 | 29.2% |
| Equity (SPY) | 9.7% | 13.9% | 0.41 | 35.2% |
| Gold (GLD) | -10.5% | 29.0% | -0.39 | 19.2% |
| Commodities (DBC) | 28.2% | 21.5% | 1.05 | -17.1% |
| Real Estate (VNQ) | 8.8% | 14.3% | 0.34 | 18.3% |
| Bitcoin (BTCUSD) | -32.3% | 43.7% | -0.78 | 19.6% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with IMNM | |
|---|---|---|---|---|
| IMNM | -4.2% | 88.0% | 0.33 | - |
| Sector ETF (XLV) | 7.7% | 15.4% | 0.30 | 25.1% |
| Equity (SPY) | 10.5% | 17.3% | 0.44 | 28.9% |
| Gold (GLD) | 14.0% | 19.2% | 0.58 | 6.8% |
| Commodities (DBC) | 6.8% | 19.6% | 0.23 | -6.0% |
| Real Estate (VNQ) | 0.7% | 19.0% | -0.07 | 22.3% |
| Bitcoin (BTCUSD) | -0.6% | 51.4% | 0.17 | 22.7% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with IMNM | |
|---|---|---|---|---|
| IMNM | 0.9% | 96.6% | 0.43 | - |
| Sector ETF (XLV) | 11.5% | 16.8% | 0.56 | 20.5% |
| Equity (SPY) | 14.5% | 18.0% | 0.68 | 24.9% |
| Gold (GLD) | 10.7% | 16.6% | 0.52 | 4.6% |
| Commodities (DBC) | 7.2% | 18.2% | 0.31 | -4.8% |
| Real Estate (VNQ) | 5.8% | 20.7% | 0.23 | 17.7% |
| Bitcoin (BTCUSD) | 56.3% | 66.3% | 0.96 | 14.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Updated 11/18/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 11/9/2026 | -3.7% | -9.0% | |
| 8/11/2026 | 6.6% | 5.0% | -4.9% |
| 5/12/2026 | -2.2% | -13.4% | -19.1% |
| 3/3/2026 | 4.5% | 1.5% | 4.2% |
| 11/6/2025 | -1.7% | 6.5% | 23.0% |
| 8/6/2025 | -5.6% | -4.3% | 0.6% |
| 5/12/2025 | -0.4% | 0.9% | 19.5% |
| 3/19/2025 | 1.1% | -17.3% | -7.7% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 9 | 11 | 10 |
| # Negative | 13 | 11 | 11 |
| Median Positive | 6.6% | 6.5% | 11.5% |
| Median Negative | -4.1% | -11.6% | -7.7% |
| Max Positive | 17.4% | 23.5% | 46.5% |
| Max Negative | -10.4% | -27.6% | -44.0% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 11/9/2026 | -3.7% | -9.0% | |
| 8/11/2026 | 6.6% | 5.0% | -4.9% |
| 5/12/2026 | -2.2% | -13.4% | -19.1% |
| 3/3/2026 | 4.5% | 1.5% | 4.2% |
| 11/6/2025 | -1.7% | 6.5% | 23.0% |
| 8/6/2025 | -5.6% | -4.3% | 0.6% |
| 5/12/2025 | -0.4% | 0.9% | 19.5% |
| 3/19/2025 | 1.1% | -17.3% | -7.7% |
| 11/13/2024 | -3.9% | -19.5% | 8.5% |
| 8/12/2024 | 7.0% | 13.1% | 14.4% |
| 5/14/2024 | -5.7% | -11.6% | 2.5% |
| 3/28/2024 | -10.4% | -17.9% | -44.0% |
| 11/9/2023 | -5.5% | -7.4% | -14.4% |
| 8/9/2023 | -2.1% | 3.6% | -2.5% |
| 5/5/2023 | -4.1% | 13.0% | -8.3% |
| 3/16/2023 | 9.2% | 14.0% | 2.3% |
| 11/14/2022 | 0.6% | -27.6% | -7.1% |
| 8/5/2022 | 17.4% | 21.6% | 24.7% |
| 5/12/2022 | 10.4% | 23.5% | 46.5% |
| 5/12/2021 | -9.5% | -5.2% | -3.9% |
| 3/25/2021 | 0.2% | 1.6% | -12.9% |
| 11/17/2020 | -5.7% | -10.2% | -6.3% |
| SUMMARY STATS | |||
| # Positive | 9 | 11 | 10 |
| # Negative | 13 | 11 | 11 |
| Median Positive | 6.6% | 6.5% | 11.5% |
| Median Negative | -4.1% | -11.6% | -7.7% |
| Max Positive | 17.4% | 23.5% | 46.5% |
| Max Negative | -10.4% | -27.6% | -44.0% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 09/30/2026 | 11/09/2026 | 10-Q |
| 06/30/2026 | 08/11/2026 | 10-Q |
| 03/31/2026 | 05/12/2026 | 10-Q |
| 12/31/2025 | 03/03/2026 | 10-K |
| 09/30/2025 | 11/06/2025 | 10-Q |
| 06/30/2025 | 08/06/2025 | 10-Q |
| 03/31/2025 | 05/12/2025 | 10-Q |
| 12/31/2024 | 03/19/2025 | 10-K |
| 09/30/2024 | 11/13/2024 | 10-Q |
| 06/30/2024 | 08/12/2024 | 10-Q |
| 03/31/2024 | 05/14/2024 | 10-Q |
| 12/31/2023 | 03/28/2024 | 10-K |
| 09/30/2023 | 11/09/2023 | 10-Q |
| 06/30/2023 | 08/09/2023 | 10-Q |
| 03/31/2023 | 05/05/2023 | 10-Q |
| 12/31/2022 | 03/16/2023 | 10-K |
| Report Date | Filing Date | Filing |
|---|---|---|
| 09/30/2026 | 11/09/2026 | 10-Q |
| 06/30/2026 | 08/11/2026 | 10-Q |
| 03/31/2026 | 05/12/2026 | 10-Q |
| 12/31/2025 | 03/03/2026 | 10-K |
| 09/30/2025 | 11/06/2025 | 10-Q |
| 06/30/2025 | 08/06/2025 | 10-Q |
| 03/31/2025 | 05/12/2025 | 10-Q |
| 12/31/2024 | 03/19/2025 | 10-K |
| 09/30/2024 | 11/13/2024 | 10-Q |
| 06/30/2024 | 08/12/2024 | 10-Q |
| 03/31/2024 | 05/14/2024 | 10-Q |
| 12/31/2023 | 03/28/2024 | 10-K |
| 09/30/2023 | 11/09/2023 | 10-Q |
| 06/30/2023 | 08/09/2023 | 10-Q |
| 03/31/2023 | 05/05/2023 | 10-Q |
| 12/31/2022 | 03/16/2023 | 10-K |
| 09/30/2022 | 11/14/2022 | 10-Q |
| 06/30/2022 | 08/05/2022 | 10-Q |
| 03/31/2022 | 05/12/2022 | 10-Q |
| 12/31/2021 | 03/28/2022 | 10-K |
| 09/30/2021 | 11/15/2021 | 10-Q |
| 06/30/2021 | 08/16/2021 | 10-Q |
| 03/31/2021 | 05/12/2021 | 10-Q |
| 12/31/2020 | 03/25/2021 | 10-K |
| 09/30/2020 | 11/16/2020 | 10-Q |
| 06/30/2020 | 10/05/2020 | 424B4 |
Insider Activity
Updated 9/15/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Higgins, Jack | Chief Scientific Officer | Direct | Sell | 9152026 | 25.32 | 13,200 | 334,224 | 1,647,066 | Form |
| 2 | Barchas, Isaac | Direct | Sell | 8122026 | 27.25 | 11,048 | 301,058 | 2,512,750 | Form | |
| 3 | Barchas, Isaac | See footnote | Sell | 8122026 | 26.23 | 62,291 | Form | |||
| 4 | Barchas, Isaac | See footnote | Sell | 8122026 | 26.07 | 10,125 | 263,959 | 1,623,926 | Form | |
| 5 | Barchas, Isaac | See footnote | Sell | 8102026 | 26.06 | 15,248 | 397,363 | 1,887,161 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Higgins, Jack | Chief Scientific Officer | Direct | Sell | 9152026 | 25.32 | 13,200 | 334,224 | 1,647,066 | Form |
| 2 | Barchas, Isaac | Direct | Sell | 8122026 | 27.25 | 11,048 | 301,058 | 2,512,750 | Form | |
| 3 | Barchas, Isaac | See footnote | Sell | 8122026 | 26.23 | 62,291 | Form | |||
| 4 | Barchas, Isaac | See footnote | Sell | 8122026 | 26.07 | 10,125 | 263,959 | 1,623,926 | Form | |
| 5 | Barchas, Isaac | See footnote | Sell | 8102026 | 26.06 | 15,248 | 397,363 | 1,887,161 | Form | |
| 6 | Barchas, Isaac | See footnote | Sell | 8102026 | 26.06 | 20,840 | 543,090 | 2,284,524 | Form | |
| 7 | Horn, Kinney | CHIEF BUSINESS OFFICER | Direct | Sell | 8062026 | 25.09 | 90,616 | Form | ||
| 8 | Horn, Kinney | CHIEF BUSINESS OFFICER | Direct | Sell | 7092026 | 25.00 | 1,092 | Form | ||
| 9 | Barchas, Isaac | See footnote | Sell | 7072026 | 24.20 | 16,906 | 409,125 | 2,625,797 | Form | |
| 10 | Barchas, Isaac | See footnote | Sell | 7072026 | 24.11 | 83,094 | 2,003,396 | 3,023,635 | Form | |
| 11 | Lechleider, Robert | Chief Medical Officer | Direct | Sell | 7072026 | 22.62 | 55,000 | 1,244,331 | 357,575 | Form |
| 12 | Barchas, Isaac | See footnote | Sell | 7022026 | 22.59 | 100,000 | 2,258,848 | 4,709,789 | Form | |
| 13 | Barchas, Isaac | See footnotes | Sell | 7022026 | 21.12 | 101,050 | 2,134,176 | 6,515,604 | Form | |
| 14 | Lechleider, Robert | Chief Medical Officer | Direct | Sell | 6292026 | 19.85 | 55,000 | 1,091,662 | 313,704 | Form |
| 15 | Rosett, Max | Chief Financial Officer | Direct | Sell | 6172026 | 18.23 | 60,000 | 1,093,800 | 985,095 | Form |
| 16 | Bienaime, Jean Jacques | Direct | Sell | 6092026 | 19.41 | 10,500 | 203,820 | 638,927 | Form | |
| 17 | Bienaime, Jean Jacques | Direct | Buy | 6092026 | 19.45 | 10,500 | 204,260 | 844,566 | Form | |
| 18 | Bienaime, Jean Jacques | Direct | Buy | 5192026 | 20.70 | 5,000 | 103,500 | 898,690 | Form | |
| 19 | Higgins, Jack | Chief Scientific Officer | Direct | Sell | 4032026 | 21.64 | 9,438 | 204,238 | 476,080 | Form |
| 20 | Rosett, Max | Chief Financial Officer | Direct | Sell | 4032026 | 21.92 | 65,000 | 1,424,916 | 1,184,588 | Form |
| 21 | Siegall, Clay B | President and CEO | Direct | Buy | 3312026 | 19.67 | 25,450 | 500,602 | 13,586,148 | Form |
| 22 | Wagenheim, Philip | Direct | Sell | 3232026 | 20.65 | 28,200 | 582,330 | 7,044,686 | Form | |
| 23 | Wagenheim, Philip | Direct | Sell | 3232026 | 20.47 | 36,800 | 753,296 | 7,560,533 | Form | |
| 24 | Bienaime, Jean Jacques | Direct | Buy | 3122026 | 21.55 | 1,000 | 21,550 | 827,843 | Form | |
| 25 | Bienaime, Jean Jacques | Direct | Buy | 3122026 | 22.12 | 1,000 | 22,120 | 827,620 | Form | |
| 26 | Siegall, Clay B | President and CEO | Direct | Buy | 12302025 | 21.15 | 4,729 | 100,018 | 14,070,122 | Form |
| 27 | Barchas, Isaac | See footnotes | Sell | 12232025 | 21.72 | 371,949 | 8,078,732 | 44,361,623 | Form | |
| 28 | Barchas, Isaac | See footnote | Sell | 12232025 | 22.34 | 11,251 | 251,347 | 45,376,584 | Form | |
| 29 | Siegall, Clay B | President and CEO | Direct | Buy | 12222025 | 20.48 | 7,278 | 149,053 | 17,623,552 | Form |
| 30 | Tsai, Philip | Chief Technical Officer | Direct | Buy | 12222025 | 20.49 | 10,000 | 204,900 | 887,217 | Form |
| 31 | Siegall, Clay B | President and CEO | Direct | Buy | 12182025 | 21.50 | 46,511 | 999,986 | 18,344,810 | Form |
Investor Activity (13F)
Updated Nov 20, 2026Active managers (13F portfolio over $250M, at least 3 holdings) with a position over $5M that is either over 10% of their portfolio or held in a concentrated book of 50 or fewer total positions. Index/ETF, sovereign, bank, community-bank and charitable/donor-advised filers are excluded.
| Active Manager |
|---|
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.